[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bioteck S.p.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100650449","reducing-the-time-interval-for-implant-placement-after-extraction-socket-preservation-using-bioteck-materials-and-oitech-implant-system-100650449",false,"NCT07746869","Reducing the Time Interval for Implant Placement After Extraction Socket Preservation Using BIOTECK Materials and OITECH Implant System","Reducing the Time Interval for Implant Placement After Extraction Socket Preservation Using BIOTECK Materials and OITECH Implant System: A Randomized Controlled Clinical Study","BIO-OI-TECHEIP","Inclusion Criteria:\n\n1. Age: ≥ 18 years.\n2. Good general health. Need for extraction of incisors, canines, or premolars due to caries, endodontic complications, root fracture, or prosthetic reasons.\n3. Presence of three intact alveolar walls following tooth extraction, with a defect in the vestibular wall (\\\u003C50%).\n4. Need for treatment with single-tooth implants, with adjacent teeth and occlusal antagonists present.\n5. Sufficient available bone, as assessed by CBCT, for the placement of implants 3.6 mm in diameter and 10 mm in length.\n6. Periodontal health with intact or reduced periodontium. Full-mouth plaque and bleeding scores \\\u003C 20%.\n7. Ability and willingness to follow the study procedures and instructions.\n\nExclusion Criteria:\n\n1. Compromised health status. Presence of any systemic condition, such as uncontrolled diabetes mellitus, cancer, HIV, disorders that impair wound healing, chronic high-dose steroid therapy, intravenous and oral bisphosphonate therapy, metabolic bone diseases, a history of head and neck radiation, or any other immunosuppressive therapy that contraindicates oral surgical treatment.\n2. Absence of adjacent teeth or opposing occlusal teeth.\n3. The missing tooth is a molar.\n4. More than one defect in the bone wall or a buccal defect \\>50%.\n5. Allergy or hypersensitivity to medications or any product used during the study.\n6. Regular use of tobacco (defined as \\>1 cigarette per day) or chewing tobacco, even within the 3 months prior to enrollment.\n7. Untreated periodontitis.\n8. Acute periapical or periodontal infection.\n9. Oral plaque and\u002For bleeding \\> 20%.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","This randomized controlled clinical study aims to compare two healing periods (4 vs 6 months) after extraction socket preservation using equine-derived enzymatically treated biomaterials (BIOTECK® system), prior to implant placement with the OITECH implant system. The study evaluates whether early implant placement at 4 months provides comparable or non-inferior outcomes to the conventional 6-month protocol in terms of primary implant stability, bone quality, and histological bone regeneration. Secondary outcomes include marginal bone level maintenance, peri-implant tissue health, implant survival, and the incidence of complications during follow-up. The goal is to generate clinical evidence to optimize the timing of implant placement without altering established treatment protocols.",[25],"Alveolar Bone Resorption",[27,28,29],"Activabone® Mouldable","HEART®","Xenomatrix®","NOT_YET_RECRUITING","2026-07-30",{"date":33,"type":34},"2026-08-05","ACTUAL",{"date":36,"type":21},"2026-09",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Bioteck S.p.A.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100645290","non-surgical-treatment-of-peri-implant-pockets-with-h42-100645290","NCT07680491","Non-surgical Treatment of Peri-implant Pockets With H42","H42","Inclusion Criteria:\n\n* Men or women with age ≥ 25 and ≤ 65 years.\n* Subjects affected by peri-implant pockets with probing depth (PD) in the range between 6 to 8 mm.\n* Each subject can have from 1 to 5 defects.\n* Subjects willing to provide signed informed consent to clinical investigation participation.\n\nExclusion Criteria:\n\n* Use of aspirin and antiplatelet agents a week before treatment.\n* Subjects smokers ≥ 10 cigarettes per day.\n* Subjects presenting current or previous bleeding disorders.\n* Subjects taking or having indications for anticoagulant therapy.\n* Concomitant treatments or procedures to improve gum health over the last six months before the clinical investigation enrolment, such as HA gel treatments, injection of fillers, and surgery.\n* Subjects suffering from infectious diseases, including herpes simplex infection, active hepatitis, or human immunodeficiency virus.\n* Subjects with dental aesthetic surgery in the preceding 12 months before the clinical investigation enrolment.","25 Years","65 Years",{"count":53,"type":21},56,"This prospective, observational study evaluates the efficacy and safety of H42 non-surgical treatment for peri-implant pockets. The trial involves 56 patients, with 28 subjects receiving the H42 treatment and 28 acting as a control group to monitor soft tissue healing and bone level changes.\n\nClinical outcomes focus on Pocket Probing Depth (PPD) and Silness and Löe Plaque Index (PI) measured at baseline, 1 month, and 3 months. Gingival inflammation, pain intensity on a 0-10 NRS scale, and absence of infection are monitored at baseline, 7, 14, and 21 days, and at 1 and 3 months. Additionally, a five-point tissue assessment evaluates color, suppuration, granulation tissue, bleeding, and incision margins. Radiographic analysis at baseline and 3 months uses standardized periapical x-rays to measure bone level, intra-bony defect height, width, and angulation. Safety is assessed through the continuous registration of adverse events.",[56],"Peri-implantitis",[48],"RECRUITING","2026-07-01",{"date":61,"type":34},"2026-07-02",{"date":63,"type":34},"2025-12-03",{"date":65,"type":21},"2027-09-30",{"name":40,"class":41},""]